Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SION-451 · 1 trial · 1 indication
Adverse reactions to the study drug combination SION-451 and SION-109 will be measured.
Adverse events to the study drug combination SION-451 and SION-2222 will be measured
| Arm | Type | Description |
|---|---|---|
| SION-451 + SION-2222 | EXPERIMENTAL | All participants who receive SION-451 in combination with SION-2222 |
| Placebo matched to SION-451 and SION-2222 | PLACEBO_COMPARATOR | - |
| SION 451 + SION 109 | EXPERIMENTAL | All participants who receive SION-451 in combination with SION-109 |
| Placebo matched to SION-451 and SION-109 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SION-451 | DRUG | * Pharmaceutical form: tablet * Route of administration: oral |
| SION-2222 | DRUG | * Pharmaceutical form: capsule * Route of administration: oral |
| SION-109 | DRUG | * Pharmaceutical form: tablet * Route of administration: oral |
| Placebo SION-451 | DRUG | Placebo matched to SION-451 |
| Placebo SION-2222 | DRUG | Placebo matched to SION-2222 |
| Placebo SION-109 | DRUG | Placebo matched to SION-109 |
Inclusion Criteria: 1. Healthy male or female adult participants aged 18 to 55 years, inclusive, at the time of consent. 2. Weight of at least 45 kg and body mass index between 18.0 and 32.0 kg/m2, inclusive, at Screening. 3. Participant is willing to abstain from alcohol, caffeine, smoking and nic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
SION-451 is an investigational small molecule being developed for the treatment of Cystic Fibrosis (CF). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in combination with other modulators to potentially address the underlying cause of the disease.
SION-451 targets the CFTR protein, which is defective in people with Cystic Fibrosis. By modulating this protein, the drug aims to restore its function, potentially improving chloride transport and reducing the symptoms associated with the disease. This mechanism is being evaluated in early-stage clinical trials.
SION-451 is being developed by Sionna Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol SION. The company is conducting clinical trials to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy participants and individuals with Cystic Fibrosis.
SION-451 is in Phase 1 clinical development. The drug is currently being studied in a randomized, double-blind, placebo-controlled trial to assess its safety, tolerability, and pharmacokinetics. It is an investigational agent and has not yet received regulatory approval for any indication.
SION-451 is being evaluated in a Phase 1 clinical trial with the identifier NCT07035990. This study is recruiting 144 healthy participants in Australia and is investigating multiple dose combinations of SION-451 with complementary modulators SION-2222 and SION-109. The trial is randomized, double-blind, and placebo-controlled.
No, SION-451 is a distinct investigational drug from SION-2222 and SION-109. These are separate complementary modulators being studied in combination with SION-451 in a clinical trial. Each agent has its own unique properties and is being evaluated together to assess their combined effects in treating Cystic Fibrosis.